Company Overview - GSK (formerly GlaxoSmithKline) is one of the largest pharmaceutical and biotech companies globally, with a market capitalization of approximately $73 billion [1]. Investment Philosophy - The investment philosophy emphasizes the importance of compounding, dividend reinvesting, and patient investing through various market conditions to achieve significant rewards [1]. - The approach combines steady accumulation of high-quality assets with high-risk/high-reward opportunities, underappreciated turnaround plays, and transformative technologies [1]. Educational Background - The individual has over 20 years of teaching experience at the college/university level and holds a PhD from Brunel University, indicating a strong academic foundation [1].

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether GSK and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On this news, GSK's American Deposita ...

Core Viewpoint - HengRui Pharma has entered into a collaboration agreement with GlaxoSmithKline (GSK) for the global exclusive rights to the HRS-9821 project and up to 11 additional projects, excluding China, which will significantly enhance HengRui's globalization efforts and provide GSK with substantial growth opportunities post-2031 [2][3] Group 1 - GSK will pay HengRui a $500 million upfront payment as part of the agreement [2] - If all projects are exercised and milestones achieved, HengRui could receive potential milestone payments totaling approximately $12 billion [2] - The collaboration aims to expand GSK's research pipeline in areas such as respiratory, autoimmune, inflammation, and oncology, with all projects assessed to have the potential to become "best-in-class" or "first-in-class" [2] Group 2 - HRS-9821 is currently in clinical development for the treatment of chronic obstructive pulmonary disease (COPD) as an adjunctive maintenance therapy [2] - The agreement includes a groundbreaking large-scale collaboration plan, where HengRui will lead the development of up to 11 projects, with each project having its own financial structure [2] - HengRui's Executive Vice President and Chief Strategy Officer emphasized that this strategic partnership marks a significant milestone in HengRui's internationalization process [3]

恒瑞医药（600276）7月28日发布公告，公司与葛兰素史克(GSK)达成协议，将HRS-9821项目在中国大 陆及港澳台地区以外的全球独家权利，以及最多11个项目的全球独家选择权，有偿许可给GSK。 根据协议，恒瑞医药将获得5亿美元首付款。若所有项目均被行权且达成里程碑，恒瑞医药有资格获得 累计约120亿美元里程碑付款，并享有相应销售梯度分成。GSK可在项目完成含海外数据的Ⅰ期临床后 行使各项目的全球开发及商业化选择权。HRS-9821授权将在通过反垄断审批后生效。 公告称，协议的签署有助于拓宽HRS-9821和多个在肿瘤、呼吸、自免和炎症等治疗领域创新产品的海 外市场，为全球患者提供优质的治疗选择，也将进一步提升公司创新品牌和海外业绩。 公告还表示，公司在内生发展的基础上加强国际合作，实现研发成果的快速转化，借助国际领先的合作 伙伴覆盖海外市场，加速融入全球药物创新网络，实现产品价值最大化，让公司创新产品服务全球患 者。 其他11个项目涉及肿瘤、呼吸、自免和炎症等多个治疗领域的创新药物，目前均处于非临床研究阶段。 恒瑞医药将主导这些项目的研发，最晚至完成包括海外受试者数据的Ⅰ期临床试验。 HRS-9821 ...

Core Viewpoint - The collaboration between Heng Rui Medicine and GlaxoSmithKline (GSK) marks a significant shift in the innovative drug monetization landscape, moving from oncology to chronic diseases, particularly chronic obstructive pulmonary disease (COPD) [2][3][4] Group 1: Partnership Details - GSK will pay Heng Rui Medicine a total of $500 million as an upfront payment, and Heng Rui will license its PDE3/4 inhibitor HRS-9821 and up to 11 additional projects to GSK for global rights outside of Greater China [1] - If all projects are successfully developed and commercialized, Heng Rui could receive up to $12 billion in milestone payments, along with sales royalties [1][7] - HRS-9821 has shown strong PDE3 and PDE4 inhibition effects and is expected to be developed as a convenient dry powder inhaler (DPI) formulation [6] Group 2: Market Context - The global COPD patient population exceeds 390 million, with around 100 million in China, where the disease is the third leading cause of death [4] - Traditional COPD treatments have been limited, but recent innovations, such as Merck's acquisition of Verona Pharma for $10 billion, highlight a renewed focus on this therapeutic area [4][5] Group 3: Industry Trends - The oncology sector is experiencing saturation, with over 60% of global cancer drug pipelines featuring similar target drugs, prompting companies to seek new growth areas [2] - The collaboration between Heng Rui and GSK represents a strategic move for GSK to strengthen its respiratory disease portfolio, aligning with its focus on core business areas [8] Group 4: Future Implications - The partnership signifies a qualitative leap in Heng Rui's international strategy, moving beyond single project licensing to a platform-based collaboration model [7] - The global pharmaceutical industry is facing a "patent cliff," with significant revenue risks as patents expire, leading companies to accelerate external collaborations for new revenue streams [9][10]

Group 1 - The UK aims to reduce tariffs on steel, whisky, and pharmaceuticals during Trump's visit, with a focus on finalizing a significant US-UK trade agreement [1] - Trump's previous imposition of a 25% tariff on all imported cars and parts from the UK has led to a temporary halt in shipments from British brands like Aston Martin and Jaguar Land Rover [1] - The US is looking to ensure that only steel processed in the UK qualifies for tariff exemptions, complicating the situation for Tata Steel, which imports steel from its plants in India and the Netherlands [1] Group 2 - The UK seeks a waiver on pharmaceutical tariffs, as major companies like GlaxoSmithKline and AstraZeneca rely heavily on the US market for 42%-52% of their sales [2] - Trump has threatened to impose a 50% tariff on drugs to curb profits of UK pharmaceutical companies, but negotiations are stalled due to the UK's reluctance to lower domestic drug prices [2] - AstraZeneca has announced plans to expand its manufacturing and R&D capabilities in the US, indicating a shift in strategy in response to Trump's tariff policies [2]

Core Viewpoint - HengRui Pharma has entered into a collaboration agreement with GlaxoSmithKline (GSK) to co-develop up to 12 innovative drugs, which will enhance HengRui's globalization efforts and provide GSK with significant growth opportunities post-2031 [1] Group 1: Collaboration Details - The collaboration includes a total upfront payment of $500 million from GSK to HengRui [1][3] - HengRui will license its PDE3/4 inhibitor, HRS-9821, to GSK for global rights outside of Greater China, which is currently in clinical development for chronic obstructive pulmonary disease (COPD) [1][2] - The agreement also encompasses a groundbreaking collaborative plan to develop up to 11 additional projects, with HengRui leading the research and GSK having exclusive options for further development and commercialization [2][3] Group 2: Strategic Implications - The partnership is seen as a significant milestone in HengRui's internationalization process, leveraging GSK's strengths in drug development and global clinical networks to accelerate the entry of innovative therapies into overseas markets [2] - GSK's Chief Scientific Officer emphasized the strategic investment in validated target projects, which can significantly enhance the success rate of research and development [2] - The collaboration aims to integrate GSK's expertise in disease biology and clinical development with HengRui's capabilities in early-stage research and clinical evaluation, maximizing strategic synergies [2] Group 3: Financial Potential - If all projects are successfully developed and milestones are achieved, HengRui could qualify for potential milestone payments totaling approximately $12 billion [3] - HengRui will also be entitled to receive tiered sales royalties from GSK, excluding sales in Greater China [3]

Core Insights - Hengrui Pharma has entered into agreements with GSK to develop up to 12 innovative medicines, enhancing Hengrui's globalization strategy and providing new growth opportunities for GSK beyond 2031 [1][5] - GSK will pay $500 million in upfront fees for the agreements, which include a license for a potential best-in-class PDE3/4 inhibitor (HRS-9821) for treating chronic obstructive pulmonary disease (COPD) [1][6] Group 1: Agreements and Financials - The agreements grant GSK an exclusive worldwide license for HRS-9821, aimed at treating COPD as an add-on maintenance treatment [2][8] - The total potential value of future success-based payments to Hengrui Pharma could reach approximately $12 billion if all programmes are optioned and milestones achieved [6] Group 2: Development and Collaboration - Hengrui Pharma will lead the development of the additional 11 programmes up to the completion of phase I trials, with GSK having the option to further develop and commercialize them [4][8] - The collaboration is expected to leverage GSK's R&D expertise and global clinical network, accelerating the development of innovative therapies [5][6]

智通财经7月28日电，恒瑞医药公告，与GlaxoSmithKlineIntellectualProperty(No.3)Limited和 GlaxoSmithKlineIntellectualProperty(No.4)Limited公司（以下统称"GSK"）达成协议，将HRS-9821项目的 全球独家权利（不包括中国大陆、香港特别行政区、澳门特别行政区及台湾地区）和至多11个项目的全 球独家许可的独家选择权（不包括中国大陆、香港特别行政区、澳门特别行政区及台湾地区）有偿许可 给GSK。 恒瑞医药：将HRS-9821项目的全球独家权利和至多11个项目的全球独家许可的独家选择权有偿许可给 GSK ...

恒瑞医药公告，公司与GSK达成协议，将HRS-9821项目的全球独家权利和至多11个项目的全球独家许 可的独家选择权有偿许可给GSK。GSK将向恒瑞支付5亿美元的首付款，公司将有资格获得未来基于成 功开发、注册和销售里程碑付款的潜在总金额约120亿美元。 ...